An *in silico* mechanistic insight into HDAC8 activation facilitates the discovery of new small-molecule activators

Jintong Du ^{2,3}, Wen Li ¹, Bo Liu ³, Yingkai Zhang ^{4,5}, Jinming Yu ^{2,3}, Xuben Hou ^{1,4,*} and Hao Fang ^{1,*}

- ¹ Department of Medicinal Chemistry and Key Laboratory of Chemical Biology of Natural Products (MOE), School of Pharmacy, Shandong University, Jinan, Shandong, 250012, China;
- ² Shandong Cancer Hospital, Shandong University, Jinan, Shandong, 250012, China;
- ³ Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, 250117, China;
- ⁴ Department of Chemistry, New York University, New York, New York 10003, United States;
- ⁵ NYU-ECNU Center for Computational Chemistry, New York University-Shanghai, Shanghai 200122, China;

Corresponding authors: <u>hxb@sdu.edu.cn</u> (X.H.); <u>haofangcn@sdu.edu.cn</u> (H.F.).

Supporting Information



Fig. S1. (A) Calculated ligand volume of known HDAC8 activator TM-2-51. (B) Molecular docking results of TM-2-51. Briefly, TM-2-51 was docked in the HDAC8-substrate crystal structure (PDB: 2V5W) using AutoDock Vina with the searching volume include the whole protein structure. Top 10 scored structure of TM-2-51 were shown as stick models (colored in cornflower blue). The fluorescent substrate was presented as red ribbon with 7-Amino-4-methylcoumarin (AMC) group shown as red sticks.



Fig. S2. Three representative top-scored docking poses of TM-2-51.



Fig. S3. Predicted binding mode of known HDAC8 activators compound **4** (A) and compound **7** (B) with HDAC8-fluorescent substrate complex.



Fig. S4. Comparison of HDAC3-DAD-IP4 complex (PDB: 4A69) and HDAC8p53AMC-activator complex (Representative snapshot from MD simulation).



Fig. S5. Twenty low-molecular weight fragments from virtual screening.